Response to tabelecleucel leads to long-term survival in patients with EBV+ PTLD following HCT March 22, 2021
Dyadic plans to conduct first-in-human study of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100 March 22, 2021
Pyxis Oncology enters worldwide agreement with Pfizer to develop and commercialize novel ADCs March 22, 2021
RSS